Amanote Research
Register
Sign In
After the Approval of Dupilumab for Moderate-To-Severe Atopic Dermatitis: What Is Next on the Research Agenda?
British Journal of Dermatology
- United Kingdom
doi 10.1111/bjd.16505
Full Text
Open PDF
Abstract
Available in
full text
Categories
Dermatology
Medicine
Date
May 1, 2018
Authors
J. Schmitt
Publisher
Wiley
Related search
Efficacy and Safety of Dupilumab for the Treatment of Moderate-To-Severe Atopic Dermatitis in Adults
Oncotarget
Oncology
605 Efficacy and Safety of Dupilumab in Adolescent Patients With Moderate-To-Severe Atopic Dermatitis
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Alopecia Areata After Dupilumab for Atopic Dermatitis
JAAD Case Reports
Dermatology
Dupilumab for the Treatment of Atopic Dermatitis
Prescriber
Pharmacology
615 Dupilumab Elicits Rapid and Sustained Improvements in Itch in Adults With Moderate-To-Severe Atopic Dermatitis
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
Dupilumab Versus Cyclosporine for Treatment of Moderate-To-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index
Acta Dermato-Venereologica
Dermatology
Medicine
Effect of Moderate to Severe Atopic Dermatitis on the Prognosis of Egg Allergy Resolution
Asian Pacific Journal of Allergy and Immunology
Medicine
Allergy
Immunology
Group 2 Innate Lymphoid Cells in Patients With Severe Atopic Dermatitis on Dupilumab
Journal of Allergy and Clinical Immunology
Allergy
Immunology
Dupilumab-Induced Phenotype Switching From Atopic Dermatitis to Psoriasis
JAAD Case Reports
Dermatology
